Sophiris Presents Positive Data from Phase 3 Study of LUTS Drug Treatment at AUA 2016
News
Sophiris Bio, Inc., presented positive data from its ongoing Phase 3 clinical trial of topsalysin — assessing the drug candidate as a potential treatment for symptoms of benign prostatic hyperplasia (BPH) — as a ... Read more